In adolescents with thalassaemia-induced diabetes, dulaglutide reduced glycemic variability versus baseline and insulin.
In plain wordsDulaglutide reduced blood sugar variability versus baseline and insulin in adolescents with thalassaemia-induced diabetes.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- DecreaseGlycemic variability CV
- Study
n = 80
- Comparator
- Conventional basal-bolus insulin
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 0.75 mg weekly · subcutaneous · 24 weeksAs given in this study (human).
Measurements
- Coefficient of variation (CV)
- 39.45%
- dulaglutide group, baseline
- Coefficient of variation (CV)
- 35.05%
- dulaglutide group, week 24
- Coefficient of variation (CV)
- 39.85%
- insulin group, baseline
- Coefficient of variation (CV)
- 43.26%
- insulin group, week 24
- Standardised effect size
- 1.69 effect size
- between-group difference in CV
Source sentences
After 24 weeks, dulaglutide resulted in a significant decrease in CV (from 39.45 ± 3.97% to 35.05 ± 4.30%; p<0.001)
5 context sentences(design, population, supporting numbers)
compared with baseline levels and with the insulin group (p<0.05).
The estimated standardised effect size for the between-group difference in the CV was 1.69 (95% CI 1.16, 2.22).
Eligibility criteria were adolescents with TDT-induced diabetes aged 10-18 years, uncontrolled on metformin.
The 80 participants were randomly assigned based on a computer-generated randomisation sequence to receive either subcutaneous dulaglutide (0.75 mg weekly) or conventional basal-bolus insulin therapy.
Although the glucose management indicator decreased in the insulin group after 24 weeks compared with baseline, the CV (from 39.85 ± 4.99% to 43.26 ± 5.75%; p<0.001) and time above range were significantly increased (p<0.001).